DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Clinical trials for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY explained in plain language.
Never miss a new study
Get alerted when new DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY trials appear
Sign up with your email to follow new studies for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with devastating genetic epilepsy
Disease control OngoingThis early-stage study is testing if a medication called glycerol phenylbutyrate is safe and well-tolerated in children with rare genetic disorders that cause severe epilepsy and developmental delays. The study will enroll up to 50 children, from infants to teenagers, who have co…
Matched conditions: DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Phase: EARLY_PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for severe childhood epilepsy: Long-Term drug trial seeks to tame debilitating seizures
Disease control ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of an investigational medication called LP352 for controlling seizures in children and adults with severe forms of developmental and epileptic encephalopathy (DEE). The trial is open to participants who previously compl…
Matched conditions: DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
One-Shot gene therapy trial aims to help kids with rare brain disease
Disease control TerminatedThis early-stage trial is testing a single dose of an experimental gene therapy called CAP-002 in children aged 18 months to 8 years with a rare genetic brain condition called STXBP1 encephalopathy. The main goal is to check if the treatment is safe and tolerable, while also look…
Matched conditions: DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
Phase: PHASE1, PHASE2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC